Compare DFNS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFNS | TPST |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 30.9M |
| IPO Year | N/A | 2012 |
| Metric | DFNS | TPST |
|---|---|---|
| Price | $0.60 | $1.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.2M | 128.8K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.62 | $0.60 |
| 52 Week High | $2.68 | $12.22 |
| Indicator | DFNS | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 19.61 | 29.65 |
| Support Level | N/A | N/A |
| Resistance Level | $2.44 | $2.49 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 17.99 | 12.50 |
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.